Newsroom

For all company announcements, please refer to SGX company disclosures page.

15

October 2021

FRIDAY

The Board of Directors of iX Biopharma Ltd. is pleased to announce that at the Annual General Meeting (AGM) of the Company held by electronic means today, all resolutions set out in the Notice of AGM dated 29 September 2021 were duly passed by way of a poll vote.

The results of AGM can be found at this link.

14

October 2021

THURSDAY

iX Biopharma wishes to address key questions received from the Shareholders ahead of the upcoming annual general meeting to be held on 15 October 2021.

The questions and answers can be viewed at this link.

30

SEPTEMBER 2021

THURSDAY

iX Biopharma is pleased to announce that it has entered into an agreement with China Resources Pharmaceutical Commercial Group Co., Ltd (“CRPCG”) through its wholly-owned subsidiary China Resources Pharmaceutical Commercial Group International Trading Co., Ltd. (华润医 药商业集团国际贸易有限公司) for the licensing, supply, and distribution of Wafesil, a sublingual sildenafil wafer for the treatment of male erectile dysfunction in China.

This Licensing Agreement marks the first deal between CRPCG and iX Biopharma following the execution of a strategic cooperation framework agreement announced in April 2021, to engage in an all-round cooperation including licensing and joint-venture activities in respect of iX Biopharma’s sublingual pharmaceutical and nutraceutical products in China.

More information can be found in the attached press release.

29

September 2021

WEDNESDAY

iX Biopharma Ltd has published its Annual Report for FY2021 which can be found here.

iX Biopharma Ltd has released its letter to shareholders, and other related documents, on alternative arrangements for the upcoming Annual General Meeting of the company to be held on 15 October 2021.

AGM Letter to Shareholders

Notice of AGM

AGM Proxy Form

Registration URL Link for Shareholder attendance of the AGM:
https://complete-corp.com/ix-biopharma-agm/

Email address for submission of AGM Proxy Form:
ixbiopharma-agm@complete-corp.com

Shareholders who wish to submit questions may do so via the registration website at https://complete-corp.com/ix-biopharma-agm/ or by email to
ixbiopharma-agm@complete-corp.com

24

August 2021

TUESDAY

iX Biopharma Ltd has reported results for the second half and full financial year ended 30 June 2021.

The fourth quarter and full financial year statements can be found here.

27

July 2021

TUESDAY

iX Biopharma Ltd is pleased to announce that it has entered into an agreement with medicinal cannabis company Organic Genetics Group Limited, through its wholly-owned subsidiary iX Syrinx Pty Ltd, to supply the Company’s novel sublingual medicinal cannabis wafers in New Zealand.

The supply agreement will allow iX Biopharma to access New Zealand’s pharmaceutical market through OGG’s commercial partnership with its shareholder, ANZ Pharma. ANZ Pharma is a reseller of leading pharmaceutical, health and beauty care products with an extensive distribution network of 1,108 pharmacies comprising owned and independent pharmacies, including Green Cross Health, Chemist Warehouse, and Countdown Pharmacies across the North and South Islands of New Zealand.

The agreement comes close on the heels of the Company’s shipment of Xativa to Brazil, following the product’s inclusion in the Australian Register of Therapeutic Goods (ARTG) list of drugs approved for export

More information can be found in the attached press release.

26

July 2021

MONDAY

iX Biopharma’s rights issue closed on July 19 with valid acceptances and valid excess applications amounting to 196.2 per cent of the shares available for subscription. 48.8 million ordinary shares will be issued at an issue price of S$0.20 per share, to raise net proceeds of S$9.56 million.

These net proceeds will be used to fund manufacturing and marketing activities for the group’s products and for general working capital purposes.

More information can be found in the attached press release.

12

July 2021

MONDAY

iX Biopharma wishes to announce that the company is exploring the possibility of a spin-off of its pharmaceutical business (including medicinal cannabis) by way of a listing on the Main Board of The Stock Exchange of Hong Kong Limited (the “HKEX”) through Chapter 18A of the Rules Governing the Listing of Securities on the Stock Exchange.

More information can be found in the attached press release.

30

June 2021

WEDNESDAY

The Board of Directors refers to the announcement dated 30 June 2021 in relation to, amongst others, the lodgement of the offer information statement in connection with the proposed renounceable non-underwritten rights issues of up to 48,814,711 new ordinary shares in the capital of the Company (“Offer Information Statement”).

More information can be found in the attached announcement.  A copy of the Offer Information Statement can be viewed at this link.

28

June 2021

MONDAY

iX Biopharma Ltd has obtained export listing status for Xativa, its CBD (cannabidiol) sublingual wafer. Xativa’s inclusion in the Australian Register of Therapeutic Goods (“ARTG”) list of drugs approved for export paves the way for the Company to expand its customer base beyond Australia in line with its plans to build itself into a global medicinal cannabis provider.

Leveraging the export listing approval, the Company will commence supply of Xativa to Brazil, where it is collaborating with its partners to distribute and market the product to doctors and patients.

More information can be found in the attached press release.

15

June 2021

TUESDAY

iX Biopharma is pleased to announce that it will supply its novel Wafermine sublingual ketamine wafers in a pilot study funded by Chris O’Brien Lifehouse, one of Australia’s leading comprehensive cancer hospitals in Camperdown, Sydney. The study will evaluate the efficacy, acceptability, safety and tolerability of Wafermine administered as a first-line treatment for patients with advanced cancer suffering from moderate to severe pain.

More information can be found in the attached press release.

02

June 2021

WEDNESDAY

iX Biopharma Ltd is set to expand its current wafer production capacity at its manufacturing facility in Australia, following the installation and commissioning of its new freeze-dry production equipment. The expanded capacity will afford iX Biopharma the ability to pursue commercial partnerships, invest in marketing opportunities and expand into new markets.

More information can be found in the attached press release.

17

May 2021

MONDAY

iX Biopharma is pleased to announce that the United States Food and Drug Administration (US FDA) has granted the Company an orphan drug designation for treatment of patients with Complex Regional Pain Syndrome (CRPS) with ketamine.

More information can be found in the attached press release.

07

April 2021

WEDNESDAY

iX Biopharma is pleased to announce it has entered into a cooperation deal with China Resources Pharmaceutical Commercial Group.

More information can be found in the attached press release.

09

February 2021

TUESDAY

iX Biopharma Ltd. has reported its first half results for the financial year as of 31 December 2020.

The financial statements for the period can be found here.

10

November 2020

TUESDAY

iX Biopharma is pleased to announce that it has received positive feedback from the European Medicines Agency (EMA) in its scientific advice to the Company regarding its Phase 3 clinical development programme for Wafermine, its sublingual ketamine wafer, for registration in Europe.

More information can be found in the attached press release.

28

October 2020

WEDNESDAY

The management of iX Biopharma presented at a guest webinar hosted by Phillip Securities.

The presentation slides can be viewed here.

20

October 2020

TUESDAY

iX Biopharma is pleased to announce the approval and registration of its male erectile dysfunction drug, Silcap, in Singapore

More information can be found in the attached press release.

16

October 2020

FRIDAY

The Board of Directors of iX Biopharma Ltd. is pleased to announce that at the Annual General Meeting (AGM) of the Company held by electronic means today, all resolutions set out in the Notice of AGM dated 1 October 2020 were duly passed by way of a poll vote.

The results of AGM can be found at this link.

A Corporate Update was also presented at the end of the AGM. The presentation slides and video recording are available here:

Corporate Update presentation slides

Link to video recording: https://youtu.be/hYNDn4Tb3uc

14

October 2020

WEDNESDAY

iX Biopharma wishes to address key questions received from the Shareholders ahead of the upcoming annual general meeting to be held on 16 October 2020.

The questions and answers can be viewed at this link.

01

October 2020

THURSDAY

iX Biopharma Ltd has published its Annual Report for FY2020 which can be found here.

iX Biopharma Ltd has released its letter to shareholders, and other related documents, on alternative arrangements for the upcoming Annual General Meeting of the company to held on 16 October 2020.

AGM Letter to Shareholders

Notice of AGM

AGM Proxy Form

Registration URL Link for Shareholder attendance of the AGM:
https://complete-corp.com.sg/ix-biopharma-agm/

Email address for submission of AGM Proxy Form:
ixbiopharma-agm@complete-corp.com.sg

Shareholders who wish to submit questions may do so via the registration website at https://complete-corp.com.sg/ix-biopharma-agm/ or by email to ixbiopharma-agm@complete-corp.com.sg

28

September 2020

MONDAY

iX Biopharma Ltd is pleased to announce that it has secured TGA GMP license for its testing laboratory.

More information can be found in the attached press release.

21

September 2020

MONDAY

iX Biopharma Ltd is pleased to announce that it has been granted a patent in Israel for its WaferiX drug delivery technology.

More information can be found in the attached press release.

09

September 2020

WEDNESDAY

iX Biopharma Ltd has announced the allotment and issue of 44,491,299 Subscription Shares on 8 September 2020.

The announcement can be found here.

07

September 2020

MONDAY

The minutes for iX Biopharma’s Extraordinary General Meeting held on Friday, 4th September can be found here.

04

September 2020

FRIDAY

iX Biopharma Ltd has reported results of the extraordinary general meeting held on Friday, 4 September 2020 to seek shareholders’ approval for the proposed allotment and issue of 44,491,299 new ordinary shares.

The results can be found here.

28

August 2020

FRIDAY

iX Biopharma Ltd has reported results for the second half and full financial year ended 30 June 2020.

The fourth quarter financial statements for the period can be found here.

28

August 2020

FRIDAY

iX Biopharma Ltd has issued its response to address key questions received from the Shareholders ahead of the upcoming extraordinary general meeting to be held on 4 September 2020 and has provided an update of the financial effects of the proposed placement of 44,491,299 new ordinary shares.

More information on the Q&A can be found in the attached press release. The financial effects of the proposed placement can be viewed at this link.

11

August 2020

TUESDAY

The Directors of iX Biopharma Ltd are convening an extraordrinary general meeting of the Company to be held by way of electronic means on 4 September 2020 at 10 a.m. to seek Shareholders’ approval for the proposed allotment and issue of 44,491,299 new ordinary shares.

Letter to Shareholders

Placement Circular

EGM Proxy For

Registration URL Link for Shareholder attendance of the EGM:
https://complete-corp.com.sg/ix-biopharma-egm/

Email address for submission of EGM Proxy Form:
ixbiopharma-egm@complete-corp.com.sg

Shareholders who wish to submit questions may do so via the registration website at https://complete-corp.com.sg/ix-biopharma-egm/ or by email to ixbiopharma-egm@complete-corp.com.sg

27

August 2020

THURSDAY

A change in particulars of subscriber has been announced for the proposed placement of 44,491,299 new ordinary shares in the capital of iX Biopharma Ltd.

Please refer to the attachment in relation to the Change in Particulars of Subscriber.

04

August 2020

FRIDAY

iX Biopharma Ltd is pleased to announce the allowance of WaferiX Patent by United States Patent and Trademark Office, enhancing Wafermine Intellectual Property Protection.

More information can be found in the attached press release.

29

July 2020

WEDNESDAY

iX Biopharma Ltd has announced a proposed placement of 44,491,299 new ordinary shares.

More information can be found in the attached press release.

30

June 2020

TUESDAY

iX Biopharma Ltd is pleased to announce robust uptake of Xativa following its launch in Australia at the end of April 2020. Its initial production runs of approximately 1700 boxes of Xativa, a sublingual medicinal cannabidiol (“CBD”) wafer, have been fully sold.

More information can be found in the attached press release.

09

June 2020

TUESDAY

iX Biopharma Ltd is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for its patent application entitled “Fast Dissolving Solid Dosage Form” (U.S. Patent Application No. 13/504,309).

More information can be found in the attached press release.

26

May 2020

TUESDAY

iX Biopharma Ltd. is pleased to announce that it has commenced supply of Wafesil® and Silcap®, which are medicines for the treatment of male erectile dysfunction, through telemedicine in Australia.

More information can be found in the attached press release.

11

May 2020

MONDAY

Read our update on impact of COVID-19 on business operations from iX Biopharma Chairman & CEO here.

06

May 2020

WEDNESDAY

iX Biopharma Group’s Xativa product, the world’s first medicinal cannabis sublingual wafer, has been featured on Channel 9 News Brisbane.

Watch the news feature here.

Read more